Stock Events

Stock Events

HLS Therapeutics 

C$4.37
5
+C$0+0% Today

Statistics

Day High
4.4
Day Low
4.29
52W High
5.77
52W Low
3.93
Volume
8,200
Avg. Volume
9,569
Mkt Cap
136.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 23
C$0.05
Mar 23
C$0.05
Dec 22
C$0.05
Sep 22
C$0.05
Jun 22
C$0.05
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.15
-0.11
-0.07
-0.03
Expected EPS
-0.12
Actual EPS
N/A

Financials

-34.59%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
159.58MRevenue
-55.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HLS.TO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes in the cardiovascular and metabolic disease areas, similar to HLS Therapeutics' focus.
Novartis
NVS
Mkt Cap237.61B
Novartis offers products in the cardiovascular area, directly competing with HLS Therapeutics' offerings.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of pharmaceutical products including those for cardiovascular health, competing with HLS Therapeutics.
Merck
MRK
Mkt Cap214.76B
Merck produces medications in various therapeutic areas, including cardiovascular diseases, similar to HLS Therapeutics.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb manufactures drugs for cardiovascular diseases, directly competing with HLS Therapeutics.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a diverse product line that includes cardiovascular drugs, competing in the same market as HLS Therapeutics.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on cardiovascular therapy among other areas, positioning it as a competitor to HLS Therapeutics.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a portfolio that includes cardiovascular drugs, making it a competitor to HLS Therapeutics.
Sanofi
SNY
Mkt Cap124.45B
Sanofi produces a range of pharmaceuticals including those for cardiovascular health, competing with HLS Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson offers products across multiple healthcare areas, including cardiovascular, competing with HLS Therapeutics.

About

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
Show more...
CEO
Mr. Craig Stuart Millian M.B.A.
Employees
92
Country
CA
ISIN
CA40390B1094

Listings

OTC Link
US
HLTRF
TO
CA
HLS.TO
F
DE
74D.F

0 Comments

Share your thoughts

FAQ

What is HLS Therapeutics stock price today?▼
The current price of HLS.TO is C$4.37 CAD — it has increased by +0% in the past 24 hours. Watch HLS Therapeutics stock price performance more closely on the chart.
What is HLS Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange HLS Therapeutics stocks are traded under the ticker HLS.TO.
Is HLS Therapeutics stock price growing?▼
HLS.TO stock has fallen by -0.46% compared to the previous week, the month change is a -2.89% fall, over the last year HLS Therapeutics has showed a -8% decrease.
What is HLS Therapeutics market cap?▼
Today HLS Therapeutics has the market capitalization of 136.67M
When is the next HLS Therapeutics earnings date?▼
HLS Therapeutics is going to release the next earnings report on May 07, 2026.
What were HLS Therapeutics earnings last quarter?▼
HLS.TO earnings for the last quarter are -0.05 CAD per share, whereas the estimation was -0.04 CAD resulting in a -33.33% surprise. The estimated earnings for the next quarter are N/A CAD per share.
What is HLS Therapeutics revenue for the last year?▼
HLS Therapeutics revenue for the last year amounts to 159.58M CAD.
What is HLS Therapeutics net income for the last year?▼
HLS.TO net income for the last year is -55.2M CAD.
Does HLS Therapeutics pay dividends?▼
Yes, HLS.TO dividends are paid quarterly. The last dividend per share was 0.05 CAD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does HLS Therapeutics have?▼
As of April 01, 2026, the company has 92 employees.
In which sector is HLS Therapeutics located?▼
HLS Therapeutics operates in the Health Care sector.
When did HLS Therapeutics complete a stock split?▼
HLS Therapeutics has not had any recent stock splits.
Where is HLS Therapeutics headquartered?▼
HLS Therapeutics is headquartered in Etobicoke, CA.